Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLS NASDAQ:CNTA NASDAQ:INDV NYSE:PRME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$25.73+3.3%$25.33$16.10▼$35.72$3.15B0.692.35 million shs3.26 million shsCNTACentessa Pharmaceuticals$22.83+2.4%$19.66$9.60▼$24.57$2.99B1.571.08 million shs1.37 million shsINDVIndivior$24.15+0.3%$23.45$7.33▼$25.10N/A0.72.19 million shs968,530 shsPRMEPrime Medicine$6.23-3.4%$4.34$1.11▼$6.94$838.40M2.652.71 million shs3.77 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals+3.25%+11.34%-4.14%+32.36%-4.35%CNTACentessa Pharmaceuticals+2.38%-0.95%+9.50%+58.21%+46.91%INDVIndivior+0.33%+3.83%-2.07%+56.11%+155.83%PRMEPrime Medicine-3.41%-6.60%+51.21%+43.22%+75.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$25.73+3.3%$25.33$16.10▼$35.72$3.15B0.692.35 million shs3.26 million shsCNTACentessa Pharmaceuticals$22.83+2.4%$19.66$9.60▼$24.57$2.99B1.571.08 million shs1.37 million shsINDVIndivior$24.15+0.3%$23.45$7.33▼$25.10N/A0.72.19 million shs968,530 shsPRMEPrime Medicine$6.23-3.4%$4.34$1.11▼$6.94$838.40M2.652.71 million shs3.77 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals+3.25%+11.34%-4.14%+32.36%-4.35%CNTACentessa Pharmaceuticals+2.38%-0.95%+9.50%+58.21%+46.91%INDVIndivior+0.33%+3.83%-2.07%+56.11%+155.83%PRMEPrime Medicine-3.41%-6.60%+51.21%+43.22%+75.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLSApellis Pharmaceuticals 2.45Hold$33.2929.40% UpsideCNTACentessa Pharmaceuticals 2.91Moderate Buy$32.3841.81% UpsideINDVIndivior 2.88Moderate Buy$22.00-8.90% DownsidePRMEPrime Medicine 2.75Moderate Buy$8.9243.12% UpsideCurrent Analyst Ratings BreakdownLatest PRME, INDV, CNTA, and APLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025APLSApellis PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025CNTACentessa PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025INDVIndiviorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/6/2025CNTACentessa PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$28.0010/3/2025INDVIndiviorZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/27/2025APLSApellis PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025CNTACentessa PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025INDVIndiviorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/26/2025APLSApellis PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Sell$26.00 ➝ $18.009/3/2025CNTACentessa PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/3/2025CNTACentessa PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$31.00(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLSApellis Pharmaceuticals$754.65M4.31N/AN/A$1.84 per share13.98CNTACentessa Pharmaceuticals$6.85M446.30N/AN/A$3.05 per share7.49INDVIndivior$1.19BN/A$1.83 per share13.22($2.52) per shareN/APRMEPrime Medicine$4.96M169.00N/AN/A$1.37 per share4.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLSApellis Pharmaceuticals-$197.88M-$1.82N/AN/AN/A-30.24%-116.09%-26.72%11/4/2025 (Estimated)CNTACentessa Pharmaceuticals-$235.76M-$1.79N/AN/AN/AN/A-40.39%-29.87%11/11/2025 (Estimated)INDVIndivior$2M$0.6238.9514.12N/A6.65%-86.28%16.26%10/23/2025 (Estimated)PRMEPrime Medicine-$198.13M-$1.56N/AN/AN/AN/A-107.87%-74.97%N/ALatest PRME, INDV, CNTA, and APLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/4/2025Q3 2025APLSApellis Pharmaceuticals$0.73N/AN/AN/A$364.58 millionN/A10/23/2025Q3 2025INDVIndivior$0.38N/AN/AN/AN/AN/A8/12/2025Q2 2025CNTACentessa Pharmaceuticals-$0.35-$0.38-$0.03-$0.38$0.63 millionN/A7/31/2025Q2 2025APLSApellis Pharmaceuticals-$0.44-$0.33+$0.11-$0.33$187.91 million$171.39 million7/31/2025Q2 2025INDVIndivior$0.26$0.51+$0.25$0.14$239.43 million$302.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/APRMEPrime Medicine$1.4523.21%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLSApellis Pharmaceuticals2.903.773.16CNTACentessa Pharmaceuticals0.3210.1110.12INDVIndiviorN/A0.900.76PRMEPrime MedicineN/A6.506.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLSApellis Pharmaceuticals96.29%CNTACentessa Pharmaceuticals82.01%INDVIndivior60.33%PRMEPrime Medicine70.37%Insider OwnershipCompanyInsider OwnershipAPLSApellis Pharmaceuticals6.50%CNTACentessa Pharmaceuticals7.09%INDVIndiviorN/APRMEPrime Medicine22.74%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLSApellis Pharmaceuticals770126.29 million118.08 millionOptionableCNTACentessa Pharmaceuticals200133.91 million124.42 millionOptionableINDVIndivior1,051N/AN/ANot OptionablePRMEPrime Medicine234134.57 million100.38 millionOptionablePRME, INDV, CNTA, and APLS HeadlinesRecent News About These CompaniesPrime Medicine (NYSE:PRME) Shares Up 7.8% - Still a Buy?October 8 at 2:10 PM | marketbeat.comPrime Medicine to Participate in Upcoming Investor ConferencesOctober 7 at 8:00 AM | globenewswire.comPrime Medicine, Inc. (NYSE:PRME) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 7 at 2:14 AM | marketbeat.comPrime Medicine (NYSE:PRME) Trading Up 8% - What's Next?October 2, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Stock Price Down 5.1% - What's Next?September 26, 2025 | marketbeat.comGoldman Sachs Group Inc. Lowers Stock Holdings in Prime Medicine, Inc. $PRMESeptember 26, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Gap Down - Here's What HappenedSeptember 25, 2025 | marketbeat.comPrime Medicine, Inc. $PRME Shares Purchased by Palumbo Wealth Management LLCSeptember 25, 2025 | marketbeat.comPrime Medicine Momentum Amid Pipeline Progress: Why I Choose To 'Hold' For NowSeptember 23, 2025 | seekingalpha.comStockWatch: Data, Big Name Investors Drive Prime Medicine Stock SurgeSeptember 22, 2025 | genengnews.comGPrime Medicine (NYSE:PRME) Shares Gap Up - Here's WhySeptember 18, 2025 | marketbeat.comPrime Medicine Target of Unusually High Options Trading (NYSE:PRME)September 18, 2025 | marketbeat.comWill Prime Medicine's (PRME) Innovation Messaging at CGTI Drive Lasting Competitive Advantage?September 18, 2025 | finance.yahoo.comPrime Medicine (NYSE:PRME) Stock Price Up 5.4% - Still a Buy?September 17, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Given Average Rating of "Moderate Buy" by AnalystsSeptember 14, 2025 | marketbeat.comCathie Wood’s ARK ETF adjusts stock positions, buys PRME and TWSTSeptember 9, 2025 | investing.comPrime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 8, 2025 | seekingalpha.comPrime Medicine Unveils New Prime Editing AdvancementsSeptember 8, 2025 | msn.comPrime Drink Group Terminates Rights Offering and Announces Private PlacementSeptember 4, 2025 | globenewswire.comPrime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2, 2025 | seekingalpha.comPrime Medicine, Inc. (PRME) Presents at Citi's Biopharma Back to School Conference - SlideshowSeptember 2, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRME, INDV, CNTA, and APLS Company DescriptionsApellis Pharmaceuticals NASDAQ:APLS$25.73 +0.81 (+3.25%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$25.72 0.00 (-0.02%) As of 10/9/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Centessa Pharmaceuticals NASDAQ:CNTA$22.83 +0.53 (+2.38%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$22.74 -0.09 (-0.39%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Indivior NASDAQ:INDV$24.15 +0.08 (+0.33%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$24.16 +0.01 (+0.02%) As of 10/9/2025 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Prime Medicine NYSE:PRME$6.23 -0.22 (-3.41%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$6.46 +0.23 (+3.61%) As of 05:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
